Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Overview

Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophyenolate mofetil for graft versus host disease (GVHD) prevention following allogeneic stem cell transplantation. Risk for relapse, GVHD and non-relapse mortality will be assessed. Adaptive randomization between two study arms will be performed based on T cell counts at day 60.

SparkCures ID 769
Trial Phase Phase 2
Enrollment 60 Patients
Treatments
Tags
Trial Sponsors
  • Massey Cancer Center
NCT Identifier

NCT02593123

CLOSED

This trial has completed.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria

  • Any of the following high risk or recurrent hematological malignancies:
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin lymphoma (NHL)
  • Chronic lymphocytic leukemia (CLL)
  • Multiple myeloma (MM)
  • Acute myelogenous leukemia (AML) *Note: Determination that the malignancy is high risk will be made by the investigator.
  • Investigator determination that the patient is an appropriate candidate for reduced intensity allogeneic SCT with the standard Massey Cancer Center-Virginia Commonwealth Health System Bone Marrow Transplant MCC-VCUHS BMT Program regimen employed in this trial
  • Patients with or without previous myeloablative autologous transplant
  • HLA-matched stem cell donor, either related (6/6 or 5/6 loci matched) or unrelated (8/8 or 7/8 loci matched) *Note: Unrelated donors must be matched at HLA-A, -B, -C, and -DRB1 loci. However, a single locus mismatch will be acceptable in the event a more closely matched donor is not available.
  • Age ≥ 50 to < 75 years; patients 18 to 49 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning
  • Karnofsky Performance Status of 70-100%
  • Negative serology for HIV
  • Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines
  • Ability to understand and the willingness to sign a written informed consent document *Note: The consent form must be signed and dated prior to initiation of SCT preparative treatments.

Exclusion Criteria

  • Previous therapeutic radiation therapy (RT) that exceeds critical structure tolerance doses as determined by a radiation oncologist
  • Uncontrolled viral, fungal, or bacterial infection
  • Active meningeal or central nervous system disease
  • Previous therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than 3 months ago *Note: Previous myeloablative autologous transplant is permitted but not required.
  • Pregnancy or breastfeeding
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers